Alpha Tau Medical Ltd Stock Price, News & Analysis

Alpha Tau Medical Ltd. has initiated a feasibility and safety study of its Alpha DaRT cancer therapy, treating the first patient with advanced inoperable pancreatic cancer. Conducted at Jewish General Hospital in Montreal, the study aims to recruit 30 participants with Stage II to IV pancreatic cancer. It will assess the procedure's safety and feasibility, targeting the overall response and survival rates. CEO Uzi Sofer highlighted the trial as a significant milestone in expanding Alpha DaRT's applications. The technology uses alpha radiation for targeted tumor treatment while minimizing damage to surrounding healthy tissues.

Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) announced its CFO, Raphi Levy, will present at the Jefferies Radiopharma Innovation Summit on April 3, 2023, from 3:30-4:00 PM ET in New York City. This summit focuses on innovations in the radiopharmaceutical sector. Levy will also conduct one-on-one investor meetings during the event. Founded in 2016, Alpha Tau specializes in the development of the Alpha DaRT™, a novel alpha-radiation therapy aimed at treating solid tumors. The technology was initially developed by experts from Tel Aviv University.

Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) reassured investors regarding Silicon Valley Bank's recent closure, stating no financial ties existed that would impact operations. The company develops Alpha DaRT™, a therapy aimed at treating solid tumors with targeted alpha radiation, designed to minimize damage to surrounding healthy tissue. Founded in 2016, Alpha Tau focuses on furthering its technology's commercialization. The release includes forward-looking statements, cautioning that actual results may differ due to various factors including the need for regulatory approval and potential funding challenges.

Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) reported its 2022 financial results, achieving significant milestones in cancer treatment development. The company initiated its pivotal U.S. trial for recurrent cutaneous squamous cell carcinoma (ReSTART) and received Health Canada approval for a liver cancer feasibility trial. Financially, it recorded a net loss of $33.8 million, or $0.53 per share, compared to $27.3 million, or $0.67 per share in 2021. The cash balance stands at $105.4 million, securing operational runway for at least two years. Future focuses include expanding clinical trials and increasing production capacity.

Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) has announced the enrollment of its first two patients in the pivotal multicenter ReSTART trial, focusing on the treatment of recurrent cutaneous squamous cell carcinoma (cSCC) with its Alpha DaRT™ therapy. The trial aims to enroll up to 86 patients across the U.S., Canada, Europe, and Israel to evaluate efficacy and safety. Key endpoints include overall response rates and durability of response. CEO Uzi Sofer emphasized the milestone's significance for regulatory approval and recruitment efforts. The Alpha DaRT technology is designed for localized tumor treatment while preserving healthy tissue.